68Ga-DOTATATE for tumor localization in tumor-induced osteomalacia

Diala El-Maouche, Samira M. Sadowski, Georgios Z. Papadakis, Lori Guthrie, Candice Cottle-Delisle, Roxanne Merkel, Corina Millo, Clara C. Chen, Electron Kebebew, Michael T. Collins

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

Context: Phosphaturic mesenchymal tumors (PMTs) are small, typically difficult to localize, and express somatostatin receptors. Recent work suggests imaging studies using 68Gallium (68Ga)-conjugated somatostatin peptide analogues, such as 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA)TATE, which enables somatostatin receptor imaging with positron emission tomography (PET), may be useful at identifying these tumors. Objective: Our objective was to evaluate the use of 68Ga-DOTATATE PET/computed tomography (CT) for tumor localization in tumor-induced osteomalacia (TIO). Design: This was a single-center prospective study of patients with TIO. Setting: The study was conducted at the National Institutes of Health Clinical Center between February 2014 and February 2015. Subjects: Eleven subjects (six females, five males) with TIO were included. Intervention: Subjects underwent 68Ga-DOTATATE PET/CT in addition to 111In-pentetreotide singlephoton emission CT (Octreoscan-SPECT/CT) and fluorodeoxyglucose-PET/CT (18F FDG-PET/CT) scan. Main Outcome Measures: Localization of PMTs on the previously described imaging modalities were determined. Results: The tumor was successfully localized in 6/11 (54.5%) subjects (one was metastatic). The tumor was identified by 68Ga-DOTATATE in all six cases. Both Octreoscan-SPECT/CT and 18F FDG-PET each identified the tumor in 4/6. In no cases was 68Ga-DOTATATE the only imaging study to identify the tumor. Conclusions: In this first prospective study comparing 68Ga-DOTATATE PET/CT to OctreoscanSPECT/CT and 18F FDG-PET in TIO localization, 68Ga-DOTATATE PET/CT demonstrated the greatest sensitivity and specificity, suggesting that it may be the best single study for localization of PMTs in TIO.

Original languageEnglish (US)
Pages (from-to)3575-3581
Number of pages7
JournalJournal of Clinical Endocrinology and Metabolism
Volume101
Issue number10
DOIs
StatePublished - Oct 1 2016

Fingerprint

Tumors
Positron emission tomography
Tomography
Neoplasms
Fluorodeoxyglucose F18
Positron-Emission Tomography
Somatostatin Receptors
Single-Photon Emission-Computed Tomography
Imaging techniques
Emission-Computed Tomography
Prospective Studies
Oncogenic osteomalacia
National Institutes of Health (U.S.)
Somatostatin
Positron Emission Tomography Computed Tomography
Outcome Assessment (Health Care)
Sensitivity and Specificity
Peptides
Health
pentetreotide

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Biochemistry
  • Endocrinology
  • Clinical Biochemistry
  • Biochemistry, medical

Cite this

El-Maouche, D., Sadowski, S. M., Papadakis, G. Z., Guthrie, L., Cottle-Delisle, C., Merkel, R., ... Collins, M. T. (2016). 68Ga-DOTATATE for tumor localization in tumor-induced osteomalacia. Journal of Clinical Endocrinology and Metabolism, 101(10), 3575-3581. https://doi.org/10.1210/jc.2016-2052

68Ga-DOTATATE for tumor localization in tumor-induced osteomalacia. / El-Maouche, Diala; Sadowski, Samira M.; Papadakis, Georgios Z.; Guthrie, Lori; Cottle-Delisle, Candice; Merkel, Roxanne; Millo, Corina; Chen, Clara C.; Kebebew, Electron; Collins, Michael T.

In: Journal of Clinical Endocrinology and Metabolism, Vol. 101, No. 10, 01.10.2016, p. 3575-3581.

Research output: Contribution to journalArticle

El-Maouche, D, Sadowski, SM, Papadakis, GZ, Guthrie, L, Cottle-Delisle, C, Merkel, R, Millo, C, Chen, CC, Kebebew, E & Collins, MT 2016, '68Ga-DOTATATE for tumor localization in tumor-induced osteomalacia', Journal of Clinical Endocrinology and Metabolism, vol. 101, no. 10, pp. 3575-3581. https://doi.org/10.1210/jc.2016-2052
El-Maouche D, Sadowski SM, Papadakis GZ, Guthrie L, Cottle-Delisle C, Merkel R et al. 68Ga-DOTATATE for tumor localization in tumor-induced osteomalacia. Journal of Clinical Endocrinology and Metabolism. 2016 Oct 1;101(10):3575-3581. https://doi.org/10.1210/jc.2016-2052
El-Maouche, Diala ; Sadowski, Samira M. ; Papadakis, Georgios Z. ; Guthrie, Lori ; Cottle-Delisle, Candice ; Merkel, Roxanne ; Millo, Corina ; Chen, Clara C. ; Kebebew, Electron ; Collins, Michael T. / 68Ga-DOTATATE for tumor localization in tumor-induced osteomalacia. In: Journal of Clinical Endocrinology and Metabolism. 2016 ; Vol. 101, No. 10. pp. 3575-3581.
@article{84e301c779a043b9be6c94a084374ae9,
title = "68Ga-DOTATATE for tumor localization in tumor-induced osteomalacia",
abstract = "Context: Phosphaturic mesenchymal tumors (PMTs) are small, typically difficult to localize, and express somatostatin receptors. Recent work suggests imaging studies using 68Gallium (68Ga)-conjugated somatostatin peptide analogues, such as 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA)TATE, which enables somatostatin receptor imaging with positron emission tomography (PET), may be useful at identifying these tumors. Objective: Our objective was to evaluate the use of 68Ga-DOTATATE PET/computed tomography (CT) for tumor localization in tumor-induced osteomalacia (TIO). Design: This was a single-center prospective study of patients with TIO. Setting: The study was conducted at the National Institutes of Health Clinical Center between February 2014 and February 2015. Subjects: Eleven subjects (six females, five males) with TIO were included. Intervention: Subjects underwent 68Ga-DOTATATE PET/CT in addition to 111In-pentetreotide singlephoton emission CT (Octreoscan-SPECT/CT) and fluorodeoxyglucose-PET/CT (18F FDG-PET/CT) scan. Main Outcome Measures: Localization of PMTs on the previously described imaging modalities were determined. Results: The tumor was successfully localized in 6/11 (54.5{\%}) subjects (one was metastatic). The tumor was identified by 68Ga-DOTATATE in all six cases. Both Octreoscan-SPECT/CT and 18F FDG-PET each identified the tumor in 4/6. In no cases was 68Ga-DOTATATE the only imaging study to identify the tumor. Conclusions: In this first prospective study comparing 68Ga-DOTATATE PET/CT to OctreoscanSPECT/CT and 18F FDG-PET in TIO localization, 68Ga-DOTATATE PET/CT demonstrated the greatest sensitivity and specificity, suggesting that it may be the best single study for localization of PMTs in TIO.",
author = "Diala El-Maouche and Sadowski, {Samira M.} and Papadakis, {Georgios Z.} and Lori Guthrie and Candice Cottle-Delisle and Roxanne Merkel and Corina Millo and Chen, {Clara C.} and Electron Kebebew and Collins, {Michael T.}",
year = "2016",
month = "10",
day = "1",
doi = "10.1210/jc.2016-2052",
language = "English (US)",
volume = "101",
pages = "3575--3581",
journal = "Journal of Clinical Endocrinology and Metabolism",
issn = "0021-972X",
publisher = "The Endocrine Society",
number = "10",

}

TY - JOUR

T1 - 68Ga-DOTATATE for tumor localization in tumor-induced osteomalacia

AU - El-Maouche, Diala

AU - Sadowski, Samira M.

AU - Papadakis, Georgios Z.

AU - Guthrie, Lori

AU - Cottle-Delisle, Candice

AU - Merkel, Roxanne

AU - Millo, Corina

AU - Chen, Clara C.

AU - Kebebew, Electron

AU - Collins, Michael T.

PY - 2016/10/1

Y1 - 2016/10/1

N2 - Context: Phosphaturic mesenchymal tumors (PMTs) are small, typically difficult to localize, and express somatostatin receptors. Recent work suggests imaging studies using 68Gallium (68Ga)-conjugated somatostatin peptide analogues, such as 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA)TATE, which enables somatostatin receptor imaging with positron emission tomography (PET), may be useful at identifying these tumors. Objective: Our objective was to evaluate the use of 68Ga-DOTATATE PET/computed tomography (CT) for tumor localization in tumor-induced osteomalacia (TIO). Design: This was a single-center prospective study of patients with TIO. Setting: The study was conducted at the National Institutes of Health Clinical Center between February 2014 and February 2015. Subjects: Eleven subjects (six females, five males) with TIO were included. Intervention: Subjects underwent 68Ga-DOTATATE PET/CT in addition to 111In-pentetreotide singlephoton emission CT (Octreoscan-SPECT/CT) and fluorodeoxyglucose-PET/CT (18F FDG-PET/CT) scan. Main Outcome Measures: Localization of PMTs on the previously described imaging modalities were determined. Results: The tumor was successfully localized in 6/11 (54.5%) subjects (one was metastatic). The tumor was identified by 68Ga-DOTATATE in all six cases. Both Octreoscan-SPECT/CT and 18F FDG-PET each identified the tumor in 4/6. In no cases was 68Ga-DOTATATE the only imaging study to identify the tumor. Conclusions: In this first prospective study comparing 68Ga-DOTATATE PET/CT to OctreoscanSPECT/CT and 18F FDG-PET in TIO localization, 68Ga-DOTATATE PET/CT demonstrated the greatest sensitivity and specificity, suggesting that it may be the best single study for localization of PMTs in TIO.

AB - Context: Phosphaturic mesenchymal tumors (PMTs) are small, typically difficult to localize, and express somatostatin receptors. Recent work suggests imaging studies using 68Gallium (68Ga)-conjugated somatostatin peptide analogues, such as 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA)TATE, which enables somatostatin receptor imaging with positron emission tomography (PET), may be useful at identifying these tumors. Objective: Our objective was to evaluate the use of 68Ga-DOTATATE PET/computed tomography (CT) for tumor localization in tumor-induced osteomalacia (TIO). Design: This was a single-center prospective study of patients with TIO. Setting: The study was conducted at the National Institutes of Health Clinical Center between February 2014 and February 2015. Subjects: Eleven subjects (six females, five males) with TIO were included. Intervention: Subjects underwent 68Ga-DOTATATE PET/CT in addition to 111In-pentetreotide singlephoton emission CT (Octreoscan-SPECT/CT) and fluorodeoxyglucose-PET/CT (18F FDG-PET/CT) scan. Main Outcome Measures: Localization of PMTs on the previously described imaging modalities were determined. Results: The tumor was successfully localized in 6/11 (54.5%) subjects (one was metastatic). The tumor was identified by 68Ga-DOTATATE in all six cases. Both Octreoscan-SPECT/CT and 18F FDG-PET each identified the tumor in 4/6. In no cases was 68Ga-DOTATATE the only imaging study to identify the tumor. Conclusions: In this first prospective study comparing 68Ga-DOTATATE PET/CT to OctreoscanSPECT/CT and 18F FDG-PET in TIO localization, 68Ga-DOTATATE PET/CT demonstrated the greatest sensitivity and specificity, suggesting that it may be the best single study for localization of PMTs in TIO.

UR - http://www.scopus.com/inward/record.url?scp=84991608280&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84991608280&partnerID=8YFLogxK

U2 - 10.1210/jc.2016-2052

DO - 10.1210/jc.2016-2052

M3 - Article

VL - 101

SP - 3575

EP - 3581

JO - Journal of Clinical Endocrinology and Metabolism

JF - Journal of Clinical Endocrinology and Metabolism

SN - 0021-972X

IS - 10

ER -